CRC develops through two major molecular pathways: the classic adenoma-adenocarcinoma sequence (~70% of cases) and the serrated neoplasia pathway (SNP, ~30%), characterized by hypermethylation of CpG islands and KRAS mutations 33. This evidence concerns the gene KRAS and adenocarcinoma.